Does lemongrass benefit the coronary microvasculature in a patient with hypertension and possible angina, taking nebivolol, amlodipine, and ranolazine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Lemongrass Benefit Coronary Microvasculature?

No, there is no evidence that lemongrass benefits the coronary microvasculature in patients with hypertension and possible angina. The provided clinical guidelines and research evidence contain no data supporting the use of lemongrass for coronary microvascular dysfunction or any cardiovascular condition.

Evidence-Based Management of Coronary Microvascular Dysfunction

For a patient with hypertension and possible microvascular angina already taking nebivolol, amlodipine, and ranolazine, the current regimen is already guideline-concordant:

Current Medication Rationale

  • Nebivolol (beta-blocker) + amlodipine (dihydropyridine CCB) represents the recommended first-line combination for chronic coronary syndromes, as this pairing is specifically endorsed by guidelines 1

  • Ranolazine is appropriately added as second-line therapy for microvascular angina when symptoms persist despite beta-blocker and CCB therapy, with a Class IIa, Level B recommendation from the European Society of Cardiology 2, 1

  • Ranolazine works through inhibition of the late sodium current, reducing intracellular calcium overload during ischemia without affecting heart rate or blood pressure—making it particularly suited for microvascular dysfunction 3, 4

Evidence for Ranolazine in Microvascular Angina

  • Ranolazine has been shown to improve coronary flow reserve (CFR) in patients with microvascular angina, with five studies demonstrating that patients with low baseline CFR values had significant improvement after ranolazine treatment 5

  • In a case report, ranolazine induced complete relief of angina and relevant improvement in transthoracic Doppler-derived CFR after 6 months of therapy in a patient with isolated coronary microvascular dysfunction 4

  • Ranolazine reduces mechanical compression of coronary microcirculation and may improve coronary self-regulation 2

Important Limitations and Monitoring

  • Ranolazine does not improve cardiovascular outcomes (mortality or myocardial infarction)—it is purely symptomatic therapy, as demonstrated in the MERLIN-TIMI 36 trial 1, 6

  • QTc prolongation occurs in a dose-dependent manner; obtain baseline ECG before starting ranolazine 1

  • Contraindicated in hepatic impairment or liver cirrhosis due to increased plasma levels and arrhythmia risk 2, 3, 7

  • Drug interactions: Ranolazine increases digoxin concentrations by 40-60% through P-glycoprotein inhibition and should be used cautiously with strong CYP3A inhibitors 3, 8

Alternative Add-On Options if Symptoms Persist

  • Long-acting nitrates (isosorbide mononitrate) are an equally valid Class IIa recommendation for add-on therapy if ranolazine fails to control symptoms 1, 7

  • Trimetazidine (Class IIb recommendation) may be considered if hypotension develops, as it has no hemodynamic effects 1

Bottom Line on Lemongrass

There is zero clinical evidence supporting lemongrass for coronary microvascular dysfunction. Stick with evidence-based pharmacotherapy: beta-blockers, calcium channel blockers, and ranolazine as outlined above 2, 1.

References

Guideline

Management of Coronary Microvascular Dysfunction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Mechanism of Action of Ranolazine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021

Research

Ranolazine for stable angina pectoris.

The Cochrane database of systematic reviews, 2017

Guideline

Management of Stable Angina with Nitroglycerin and Ranolazine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Clinical pharmacokinetics of ranolazine.

Clinical pharmacokinetics, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.